Importer of Controlled Substances; Notice of Application, 4612-4613 [E6-1023]
Download as PDF
<![CDATA[
4612
Federal Register / Vol. 71, No. 18 / Friday, January 27, 2006 / Notices
investigation on the basis of two
settlement agreements.
rmajette on PROD1PC67 with NOTICES
FOR FURTHER INFORMATION CONTACT:
Steven Crabb, Esq., Office of the General
Counsel, U.S. International Trade
Commission, 500 E Street, SW.,
Washington, DC 20436, telephone (202)
708–5432. Copies of non-confidential
documents filed in connection with this
investigation are or will be available for
inspection during official business
hours (8:45 a.m. to 5:15 p.m.) in the
Office of the Secretary, U.S.
International Trade Commission, 500 E
Street, SW., Washington, DC 20436,
telephone (202) 205–2000. General
information concerning the Commission
may also be obtained by accessing its
Internet server (https://www.usitc.gov).
The public record for this investigation
may be viewed on the Commission’s
electronic docket (EDIS) at https://
edis.usitc.gov. Hearing-impaired
persons are advised that information on
this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810.
SUPPLEMENTARY INFORMATION: This
investigation was instituted by the
Commission based on a complaint filed
by BenQ Corporation of Taiwan and
BenQ America Corporation of Irvine,
California. See 70 FR 35453 (June 20,
2005). The complaint alleged violations
of section 337 of the Tariff Act of 1930
in the importation into the United
States, the sale for importation, and the
sale in the United States after
importation of certain DVD/CD players
and recorders, color television receivers
and monitors, and components thereof
by reason of infringement of claims 7–
11 and 13–15 of U.S. Patent No.
5,270,821, and claims 1, 2, 4, and 5 of
U.S. Patent No. 6,683,842. The
complaint named Thomson Inc. of
Indianapolis, Indiana as the respondent.
On December 9, 2005, the private
parties filed a joint motion to terminate
the investigation on the basis of two
settlement agreements. On December 14,
2005, the Commission investigative
attorney filed a response in support of
the parties’ joint motion to terminate the
investigation.
On December 21, 2005, the ALJ issued
an ID (Order No. 16) granting the joint
motion to terminate the investigation on
the basis of the settlement agreements.
The ALJ found no indication that such
termination of the investigation would
adversely impact the public interest. No
party filed a petition to review the
subject ID.
The Commission has determined not
to review the ALJ’s ID. Accordingly, the
above-referenced investigation is hereby
terminated.
VerDate Aug<31>2005
15:17 Jan 26, 2006
Jkt 208001
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in
sections 210.21(b), and 210.42 of the
Commission’s Rules of Practice and
Procedure (19 CFR 210.21, 210.42).
By order of the Commission.
Issued: January 23, 2006.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. E6–1038 Filed 1–26–06; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
to issuing a regulation under 21 U.S.C.
952(a)(2)(B) authorizing the importation
of such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on August
17, 2005, Cerilliant Corporation, 811
Paloma Drive, Suite A, Round Rock,
Texas 78664, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in Schedule
I and II:
Drug
Schedule
[USITC SE–06–009]
Sunshine Act Meeting
United
States International Trade Commission.
TIME AND DATE: February 8, 2006 at 11
a.m.
PLACE: Room 101, 500 E Street, SW.,
Washington, DC 20436, Telephone:
(202) 205–2000.
STATUS: Open to the public.
MATTERS TO BE CONSIDERED:
1. Agenda for future meetings: none.
2. Minutes.
3. Ratification List.
4. Inv. No. 731–TA–1089 (Final)(Certain
Orange Juice from Brazil)—briefing
and vote. (The Commission is
currently scheduled to transmit its
determination and Commissioners’
opinions to the Secretary of
Commerce on or before February 21,
2006.)
5. Outstanding action jackets: None.
In accordance with Commission
policy, subject matter listed above, not
disposed of at the scheduled meeting,
may be carried over to the agenda of the
following meeting.
AGENCY HOLDING THE MEETING:
Issued: January 25, 2006.
By order of the Commission.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. 06–866 Filed 1–25–06; 3:48 pm]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in Schedule I or II and prior
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
Cathinone (1235) ..........................
Methcathinone (1237) ..................
N-Ethylamphetamine (1475) ........
Gamma
hydroxybutyric
acid
(2010).
Ibogaine (7260) ............................
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Methyl-2,5dimethoxyamphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
3,4-Methylenedioxyamphetamine
(7400).
3,4Methylenedioxymethamphetamine (7404).
3,4Methylenedioxymethamphetamine (7405).
4-Methoxyamphetamine (7411) ...
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
Etorphine (9056) ...........................
Heroin (9200) ...............................
Pholcodine (9314) ........................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
Ethylmorphine (9190) ...................
Meperidine (9230) ........................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ...................
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to import small
quantities of the listed controlled
E:\FR\FM\27JAN1.SGM
27JAN1
Federal Register / Vol. 71, No. 18 / Friday, January 27, 2006 / Notices
substances for the manufacture of
analytical reference standards.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
controlled substances may file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than February 27, 2006.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance listed in
Schedule I or II are, and will continue
to be required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Dated: January 20, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–1023 Filed 1–26–06; 8:45 am]
BILLING CODE 4410–09–P
NATIONAL FOUNDATION ON THE
ARTS AND THE HUMANITIES
Meetings of Humanities Panel
The National Endowment for
the Humanities.
ACTION: Notice of meetings.
rmajette on PROD1PC67 with NOTICES
AGENCY:
SUMMARY: Pursuant to the provisions of
the Federal Advisory Committee Act
(Public Law 92–463, as amended),
notice is hereby given that the following
meetings of Humanities Panels will be
held at the Old Post Office, 1100
VerDate Aug<31>2005
15:17 Jan 26, 2006
Jkt 208001
Pennsylvania Avenue, NW.,
Washington, DC 20506.
FOR FURTHER INFORMATION CONTACT:
Michael McDonald, Advisory
Committee Management Officer,
National Endowment for the
Humanities, Washington, DC 20506;
telephone (202) 606–8322. Hearingimpaired individuals are advised that
information on this matter may be
obtained by contacting the
Endowment’s TDD terminal on (202)
606–8282.
SUPPLEMENTARY INFORMATION: The
proposed meetings are for the purpose
of panel review, discussion, evaluation
and recommendation on applications
for financial assistance under the
National Foundation on the Arts and the
Humanities Act of 1965, as amended,
including discussion of information
given in confidence to the agency by the
grant applicants. Because the proposed
meetings will consider information that
is likely to disclose trade secrets and
commercial or financial information
obtained from a person and privileged
or confidential and/or information of a
personal nature the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy, pursuant
to authority granted me by the
Chairman’s Delegation of Authority to
Close Advisory Committee meetings,
dated July 19, 1993, I have determined
that these meetings will be closed to the
public pursuant to subsections (c) (4),
and (6) of section 552b of Title 5, United
States Code.
1. Date: February 1, 2006.
Time: 8:30 a.m. to 5 p.m.
Room: 315.
Program: This meeting will review
applications for Scholarly Editions in
American and British Literature and
Cultural History, submitted to the
Division of Research Programs at the
November 1, 2005 deadline.
2. Date: February 2, 2006.
Time: 8:30 a.m. to 5 p.m.
Room: 315.
Program: This meeting will review
applications for Collaborative Research
in American Studies, submitted to the
Division of Research Programs at the
November 1, 2005 deadline.
3. Date: February 2, 2006.
Time: 8:30 a.m. to 5:30 p.m.
Room: 415.
Program: This meeting will review
applications for Colleges and
Universities, submitted to the Office of
Challenge Grants at the November 1,
2005 deadline.
4. Date: February 3, 2006.
Time: 8:30 a.m. to 5 p.m.
Room: 315.
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
4613
Program: This meeting will review
applications for Scholarly Editions in
American History, submitted to the
Division of Research Programs at the
November 1, 2005 deadline.
5. Date: February 6, 2006.
Time: 8:30 a.m. to 5 p.m.
Room: 315.
Program: This meeting will review
applications for Collaborative Research
in Literature and the Arts, submitted to
the Division of Research Programs at the
November 1, 2005 deadline.
6. Date: February 7, 2006.
Time: 8:30 a.m. to 5:30 p.m.
Room: 415.
Program: This meeting will review
applications for History Organizations,
submitted to the Office of Challenge
Grants at the November 1, 2005
deadline.
7. Date: February 8, 2006.
Time: 8:30 a.m. to 5 p.m.
Room: 315.
Program: This meeting will review
applications for Scholarly Editions in
Classical, Medieval, and Early Modern
Texts, submitted to the Division of
Research Programs at the November 1,
2005 deadline.
8. Date: February 9, 2006.
Time: 8:30 a.m. to 5 p.m.
Room: 315.
Program: This meeting will review
applications for Collaborative Research
in European Studies, submitted to the
Division of Research Programs at the
November 1, 2005 deadline.
9. Date: February 10, 2006.
Time: 8:30 a.m. to 5 p.m.
Room: 315.
Program: This meeting will review
applications for Collaborative Research
in Africa and Asia, submitted to the
Division of Research Programs at the
November 1, 2005 deadline.
10. Date: February 28, 2006.
Time: 9:00 a.m. to 5 p.m.
Room: 415.
Program: This meeting will review
applications for Stabilization I,
submitted to the Division of
Preservation and Access at the October
1, 2005 deadline.
Michael McDonald,
Advisory Committee Management Officer.
[FR Doc. E6–1031 Filed 1–26–06; 8:45 am]
BILLING CODE 7536–01–P
NUCLEAR REGULATORY
COMMISSION
Request To Amend a License for the
Export of Radioactive Waste
Pursuant to 10 CFR 110.70(b)(4)
‘‘Public notice of receipt of an
E:\FR\FM\27JAN1.SGM
27JAN1
]]>Agencies
[Federal Register Volume 71, Number 18 (Friday, January 27, 2006)]
[Notices]
[Pages 4612-4613]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-1023]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in Schedule I or II and prior to issuing a
regulation under 21 U.S.C. 952(a)(2)(B) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with 21 CFR 1301.34(a), this is notice
that on August 17, 2005, Cerilliant Corporation, 811 Paloma Drive,
Suite A, Round Rock, Texas 78664, made application by renewal to the
Drug Enforcement Administration (DEA) to be registered as an importer
of the basic classes of controlled substances listed in Schedule I and
II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235)........................... I
Methcathinone (1237)....................... I
N-Ethylamphetamine (1475).................. I
Gamma hydroxybutyric acid (2010)........... I
Ibogaine (7260)............................ I
Tetrahydrocannabinols (7370)............... I
Mescaline (7381)........................... I
4-Bromo-2,5-dimethoxyamphetamine (7391).... I
4-Bromo-2,5-dimethoxyphenethylamine (7392). I
4-Methyl-2,5-dimethoxyamphetamine (7395)... I
2,5-Dimethoxyamphetamine (7396)............ I
3,4-Methylenedioxyamphetamine (7400)....... I
3,4-Methylenedioxymethamphetamine (7404)... I
3,4-Methylenedioxymethamphetamine (7405)... I
4-Methoxyamphetamine (7411)................ I
Psilocybin (7437).......................... I
Psilocyn (7438)............................ I
Etorphine (9056)........................... I
Heroin (9200).............................. I
Pholcodine (9314).......................... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Methylphenidate (1724)..................... II
Amobarbital (2125)......................... II
Pentobarbital (2270)....................... II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Benzoylecgonine (9180)..................... II
Ethylmorphine (9190)....................... II
Meperidine (9230).......................... II
Methadone (9250)........................... II
Dextropropoxyphene, bulk (non-dosage forms) II
(9273).
Morphine (9300)............................ II
Thebaine (9333)............................ II
Levo-alphacetylmethadol (9648)............. II
Oxymorphone (9652)......................... II
------------------------------------------------------------------------
The company plans to import small quantities of the listed
controlled
[[Page 4613]]
substances for the manufacture of analytical reference standards.
Any manufacturer who is presently, or is applying to be, registered
with DEA to manufacture such basic classes of controlled substances may
file comments or objections to the issuance of the proposed
registration and may, at the same time, file a written request for a
hearing on such application pursuant to 21 CFR 1301.43 and in such form
as prescribed by 21 CFR 1316.47.
Any such written comments or objections being sent via regular mail
may be addressed, in quintuplicate, to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, Washington, DC 20537, Attention: DEA Federal Register
Representative, Liaison and Policy Section (ODL); or any being sent via
express mail should be sent to DEA Headquarters, Attention: DEA Federal
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria,
Virginia 22301; and must be filed no later than February 27, 2006.
This procedure is to be conducted simultaneously with and
independent of the procedures described in 21 CFR 1301.34(b), (c), (d),
(e) and (f). As noted in a previous notice published in the Federal
Register on September 23, 1975, (40 FR 43745-46), all applicants for
registration to import a basic class of any controlled substance listed
in Schedule I or II are, and will continue to be required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and
21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied.
Dated: January 20, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E6-1023 Filed 1-26-06; 8:45 am]
BILLING CODE 4410-09-P
